Atossa Therapeutics Regains Nasdaq Compliance, Averting Delisting
Summary
Atossa Therapeutics announced it has regained compliance with Nasdaq's minimum bid price rule, ensuring its continued listing on The Nasdaq Capital Market.
Key Events
-
Regained Nasdaq Compliance
The company received a letter from Nasdaq confirming it had regained compliance with Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 for at least 10 consecutive trading days, met as of February 13, 2026.
-
Averts Delisting Threat
This action resolves the previously disclosed non-compliance issue from February 21, 2025, and ensures the company's common stock will continue to be listed and traded on The Nasdaq Capital Market.
-
Follows Reverse Stock Split
This successful compliance follows the 15:1 reverse stock split announced on January 26, 2026, which was a key measure to increase the per-share price and meet Nasdaq's listing standards.
Analysis
Atossa Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, a critical development that removes the immediate threat of delisting. This positive outcome follows the company's 15:1 reverse stock split, which became effective on February 2, 2026, and was a strategic move to address the non-compliance. Continued listing on Nasdaq provides stability and maintains the company's access to a major exchange, which is important for investor confidence and liquidity, especially for a life sciences company focused on product development.
At the time of this filing, ATOS was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.7M. The 52-week trading range was $3.76 to $19.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.